Table 1 Clinical characteristics included in this study from the TCGA database.
From: Prognostic and therapeutic relevance of IL2RG-related LncRNAs in clear cell renal cell carcinoma
Characteristic | Training cohort (N = 266) | Testing cohort (N = 264) | TCGA cohort (N = 530) |
|---|---|---|---|
Age (years), n (%) | |||
≤ 65 | 182 (68.4%) | 178 (67.4%) | 360 (67.9%) |
> 65 | 84 (31.6%) | 86 (32.6%) | 170 (32.1%) |
Gender, n (%) | |||
Female | 98 (36.8%) | 88 (33.3%) | 186 (35.1%) |
Male | 168 (63.2%) | 176 (66.7%) | 344 (64.9%) |
Grade, n (%) | |||
G1-2 | 122 (45.9%) | 119 (45.1%) | 241 (45.5%) |
G3-4 | 140 (52.6%) | 141 (53.4%) | 281 (53.1%) |
Unknown | 4 (1.5%) | 4 (1.5%) | 8 (1.5%) |
Stage, n (%) | |||
Stage I–II | 168 (63.2%) | 154 (58.3%) | 322 (64.1%) |
Stage III–IV | 95 (35.7%) | 110 (41.7%) | 205 (38.7%) |
Unknown | 3 (1.1%) | 0 (0%) | 3 (0.5%) |
T stage, n (%) | |||
T1–2 | 178 (66.9%) | 162 (61.4%) | 340 (64.2%) |
T3–4 | 88 (33.1%) | 102 (38.6%) | 190 (35.8%) |
M stage, n (%) | |||
M0 | 211 (79.3%) | 209 (79.2%) | 420 (79.2%) |
M1 | 41 (15.4%) | 37 (14.0%) | 78 (14.7%) |
Unknown | 14 (5.3%) | 18 (6.8%) | 32 (6.0%) |
N stage, n (%) | |||
N0 | 113 (42.5%) | 126 (47.7%) | 239 (45.1%) |
N1 | 10 (3.8%) | 6 (2.3%) | 16 (3.0%) |
Unknown | 143 (53.8%) | 132 (50.0%) | 275 (51.9%) |
